PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-05-07
DOI
10.3389/fphar.2021.692574
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update
- (2020) Jinyun Dong et al. DRUG RESISTANCE UPDATES
- Design and synthesis of α-naphthoflavone chimera derivatives able to eliminate cytochrome P450 (CYP)1B1-mediated drug resistance via targeted CYP1B1 degradation
- (2020) Li Zhou et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC)
- (2020) Hao Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- PROTACs: A novel strategy for cancer therapy
- (2020) Jing Liu et al. SEMINARS IN CANCER BIOLOGY
- Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment
- (2020) Steven Kregel et al. NEOPLASIA
- First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI).
- (2020) Daniel Peter Petrylak et al. JOURNAL OF CLINICAL ONCOLOGY
- Long non-coding RNAs towards precision medicine in gastric cancer: early diagnosis, treatment, and drug resistance
- (2020) Li Yuan et al. Molecular Cancer
- Targeting USP7-Mediated Deubiquitination of MDM2/MDMX-p53 Pathway for Cancer Therapy: Are We There Yet?
- (2020) Si-Min Qi et al. Frontiers in Cell and Developmental Biology
- Aspeterreurone A, a Cytotoxic Dihydrobenzofuran–Phenyl Acrylate Hybrid from the Deep-Sea-Derived Fungus Aspergillus terreus CC-S06-18
- (2020) Weiyi Wang et al. JOURNAL OF NATURAL PRODUCTS
- Targeting MDMX for Cancer Therapy: Rationale, Strategies, and Challenges
- (2020) De-Hua Yu et al. Frontiers in Oncology
- The E2 ubiquitin-conjugating enzyme UbcH5c: an emerging target in cancer and immune disorders
- (2020) Yuan Zhou et al. DRUG DISCOVERY TODAY
- The Role of Autophagy in Gastric Cancer Chemoresistance: Friend or Foe?
- (2020) Jing-Li Xu et al. Frontiers in Cell and Developmental Biology
- The PROTAC technology in drug development
- (2019) Yutian Zou et al. CELL BIOCHEMISTRY AND FUNCTION
- Safety and Tolerability of Antibody-Drug Conjugates in Cancer
- (2019) Anna Wolska-Washer et al. DRUG SAFETY
- Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
- (2019) Rumani Singh et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer.
- (2019) Taavi Neklesa et al. JOURNAL OF CLINICAL ONCOLOGY
- Degrading proteins in animals: “PROTAC”tion goes in vivo
- (2019) Jianping Guo et al. CELL RESEARCH
- Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs
- (2019) Miriam Girardini et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index
- (2019) Steven Coats et al. CLINICAL CANCER RESEARCH
- Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-mediated Targeted Protein Degradation
- (2019) George M Burslem et al. CANCER RESEARCH
- The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors
- (2019) Helei Hou et al. Cancer Cell International
- MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53
- (2019) Wei Wang et al. CANCER LETTERS
- Induced degradation of protein kinases by bifunctional small molecules: a next-generation strategy
- (2019) Jay C. Groppe Expert Opinion on Drug Discovery
- Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders
- (2019) Shang Su et al. JOURNAL OF MEDICINAL CHEMISTRY
- Development of Small Molecule Chimeras That Recruit AhR E3 Ligase to Target Proteins
- (2019) Nobumichi Ohoka et al. ACS Chemical Biology
- Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells
- (2019) Xupeng Mu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- PROTACs as Potential Therapeutic Agents for Cancer Drug Resistance
- (2019) Xiuyun Sun et al. BIOCHEMISTRY
- Design, synthesis and activity of novel 2,6-disubstituted purine derivatives, potential small molecule inhibitors of signal transducer and activator of transcription 3
- (2019) Xuebao Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel–Lindau (VHL) E3 Ubiquitin Ligase
- (2019) Quanju Zhao et al. JOURNAL OF MEDICINAL CHEMISTRY
- Cancer-associated fibroblast regulate proliferation and migration of prostate cancer cells through TGF-β signaling pathway
- (2019) Dai-Yu Sun et al. LIFE SCIENCES
- Targeting MDM2 for novel molecular therapy: Beyond oncology
- (2019) Wei Wang et al. MEDICINAL RESEARCH REVIEWS
- Targeted protein degradation: expanding the toolbox
- (2019) Matthieu Schapira et al. NATURE REVIEWS DRUG DISCOVERY
- PROTAC induced-BET protein degradation exhibits potent anti-osteosarcoma activity by triggering apoptosis
- (2019) Chengcheng Shi et al. Cell Death & Disease
- A novel strategy to block mitotic progression for targeted therapy
- (2019) Junlong (Jack) Chi et al. EBioMedicine
- New Promise and Opportunities for Allosteric Kinase Inhibitors
- (2019) Xiaoyun Lu et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Development of a PDEδ-Targeting PROTACs that Impair Lipid Metabolism
- (2019) Michael Winzker et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide
- (2019) Fangqing Zhang et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties
- (2019) Saul Jaime-Figueroa et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Development of selective mono or dual PROTAC degrader probe of CDK isoforms
- (2019) Fei Zhou et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Development of cell-permeable peptide-based PROTACs targeting estrogen receptor α
- (2019) Yuxuan Dai et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands
- (2019) Xin Han et al. JOURNAL OF MEDICINAL CHEMISTRY
- Design, Synthesis, and Biological Evaluation of MEK PROTACs
- (2019) Stefan Vollmer et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein
- (2019) Haibin Zhou et al. JOURNAL OF MEDICINAL CHEMISTRY
- A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
- (2019) Sajid Khan et al. NATURE MEDICINE
- Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update
- (2019) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera
- (2019) Kidae Kim et al. Scientific Reports
- PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies
- (2018) Yonghui Sun et al. CELL RESEARCH
- Recent Advances in the Development of Indazole-based Anticancer Agents
- (2018) Jinyun Dong et al. ChemMedChem
- VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma
- (2018) Jing Zhang et al. SCIENCE
- CrbnI391Vis sufficient to conferin vivosensitivity to thalidomide and its derivatives in mice
- (2018) Emma C. Fink et al. BLOOD
- Abstract 5236: ARV-110: An androgen receptor PROTAC degrader for prostate cancer
- (2018) Taavi Neklesa et al. CANCER RESEARCH
- MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53
- (2018) John Hines et al. CANCER RESEARCH
- Role of HIF-1 in Cancer Progression: Novel Insights. A Review
- (2018) Aldo Pezzuto et al. CURRENT MOLECULAR MEDICINE
- BRD4 and Cancer: going beyond transcriptional regulation
- (2018) Benedetta Donati et al. Molecular Cancer
- Ginsenoside Rb2 inhibits epithelial-mesenchymal transition of colorectal cancer cells by suppressing TGF-β/Smad signaling
- (2018) Guoliang Dai et al. PHYTOMEDICINE
- Different Degradation Mechanisms of Inhibitor of Apoptosis Proteins (IAPs) by the Specific and Nongenetic IAP-Dependent Protein Eraser (SNIPER)
- (2018) Nobumichi Ohoka et al. CHEMICAL & PHARMACEUTICAL BULLETIN
- Targeted protein degradation by PROTACs
- (2017) Taavi K. Neklesa et al. PHARMACOLOGY & THERAPEUTICS
- Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199
- (2017) Kiran Naqvi et al. Expert Review of Hematology
- BET Proteins as Targets for Anticancer Treatment
- (2017) Anastasios Stathis et al. Cancer Discovery
- Targeting the NFAT1-MDM2-MDMX Network Inhibits the Proliferation and Invasion of Prostate Cancer Cells, Independent of p53 and Androgen
- (2017) Jiang-Jiang Qin et al. Frontiers in Pharmacology
- Strategies and Approaches of Targeting STAT3 for Cancer Treatment
- (2016) Steffanie L. Furtek et al. ACS Chemical Biology
- Small-Molecule PROTACS: New Approaches to Protein Degradation
- (2016) Momar Toure et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins
- (2015) Dennis L. Buckley et al. ACS Chemical Biology
- Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling
- (2015) Natura Myeku et al. NATURE MEDICINE
- Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice
- (2015) Jianhui Chang et al. NATURE MEDICINE
- Targeting Cdc20 as a novel cancer therapeutic strategy
- (2015) Lixia Wang et al. PHARMACOLOGY & THERAPEUTICS
- Phthalimide conjugation as a strategy for in vivo target protein degradation
- (2015) G. E. Winter et al. SCIENCE
- FDA-approved small-molecule kinase inhibitors
- (2015) Peng Wu et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease
- (2013) Kadoaki Ohashi et al. JOURNAL OF CLINICAL ONCOLOGY
- Polycomb-Dependent H3K27me1 and H3K27me2 Regulate Active Transcription and Enhancer Fidelity
- (2013) Karin J. Ferrari et al. MOLECULAR CELL
- Small-Molecule Inhibitors of the Interaction between the E3 Ligase VHL and HIF1α
- (2012) Dennis L. Buckley et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Targeting the von Hippel–Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α Interaction
- (2012) Dennis L. Buckley et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- The Polycomb complex PRC2 and its mark in life
- (2011) Raphaël Margueron et al. NATURE
- Protein Knockdown Using Methyl Bestatin−Ligand Hybrid Molecules: Design and Synthesis of Inducers of Ubiquitination-Mediated Degradation of Cellular Retinoic Acid-Binding Proteins
- (2010) Yukihiro Itoh et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Impact of linker length on the activity of PROTACs
- (2010) Kedra Cyrus et al. Molecular BioSystems
- IAP-targeted therapies for cancer
- (2008) E C LaCasse et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More